


# Survival outcomes associated with radiological progressive disease subtypes in patients with atezolizumab and bevacizumab-treated HCC



Conclusion: Patients with HCC undergoing Atezo/Bev treatment, diagnosed with PD-multiple or PD-MVI, experienced poor prognosis, specifically in terms of OS.